Apogee Therapeutics, Inc. (APGE)
APGE · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2023
Who owns Apogee Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Blackrock, Inc. holds 5.5% of Common Stock, as its SCHEDULE 13G/A filed Jul 16, 2025 says.
Directors and officers
12
report now, of 15 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 16, 2025 · Common Stock
RTW Investments, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.00001 par value · reported falling below 5%, from 6% in Feb 14, 2025
Driehaus Capital Management LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · reported falling below 5%, from 15% in Aug 6, 2025
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · reported falling below 5%, from 16.8% in Apr 8, 2026
Wellington Management Group LLP
SCHEDULE 13G/A · filed Jul 8, 2026 · Common Stock · reported falling below 5%, from 8.7% in Feb 10, 2026
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13D/A · filed Sep 8, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%
Fairmount Funds Management LLC
SCHEDULE 13D/A · filed Sep 3, 2026 · Common Stock, $0.00001 par value · reported falling below 5%, from 9.99% in Jun 23, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.21% in Jan 30, 2026
What APGE reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 3, 2025.
Insider tradesForm 4
83sales
0purchases
82sales on a scheduled plan
4people selling
$174Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Harwin Peter Evan | director | 1 | $134M | 0 | 0 | $0 |
| Henderson Michael Thomas | Chief Executive Officer | 33 | $28.4M | 33 | 0 | $0 |
| Dambkowski Carl | Chief Medical Officer | 27 | $10.2M | 27 | 0 | $0 |
| Henderson Jane | Chief Financial Officer | 22 | $2.1M | 22 | 0 | $0 |